Sanofi pulls Anzemet from five markets after FDA warning

Sanofi-Aventis (SNY) is withdrawing its anti-nausea drug Anzemet from five of the 13 countries in which it is sold, pulling the drug from markets where it is only prescribed for post-chemotherapy use, rather than post-operative nausea, after FDA warned that the drug could increase the risk of an abnormal heart rhythm. Report